Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category?

References

• WHOWHO| Health technology assessment2016 Available from: http://www.who.int/health-technology-assessment/en/Accessed December 18, 2016
   Google Scholar
• GarauMMestre-FerrandizJAccess mechanisms for orphan drugs: a comparative study of selected European countriesOHE Brief200952132
   Google Scholar
• SimoensSPricing and reimbursement of orphan drugs: the need for more transparencyOrphanet J Rare Dis201164221682893
   PubMed Web of Science ®Google Scholar
• G-BAThe benefit assessment of pharmaceuticals in accordance with the German Social Code, Book Five (SGB V), section 35a – Federal Joint Committee2011 Available from: http://www.english.g-ba.de/benefitassessment/information/Accessed January 11, 2017
   Google Scholar
• Hughes-WilsonWPalmaASchuurmanASimoensSPaying for the orphan drug system: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?Orphanet J Rare Dis201277423013790
   PubMed Web of Science ®Google Scholar
• RoosJCPHyryHICoxTMOrphan drug pricing may warrant a competition law investigationBMJ2010341c647121081598
   PubMed Web of Science ®Google Scholar
• European CommissionClinical Added Value of Orphan Drugs (CAVOD)2011 Available fom: http://ec.europa.eu/chafea/documents/news/CAVOD_FinalReport_vf_corrected_281011.pdfAccessed December 15, 2016
   Google Scholar
• DenisAMergaertLFostierCCleemputISimoensSA comparative study of European rare disease and orphan drug marketsHealth Policy2010972–317317920800761
   PubMed Web of Science ®Google Scholar
• CollierJThe pharmaceutical price regulation schemeBMJ2007334759143543617332539
   PubMed Web of Science ®Google Scholar
• RawlinsMDCulyerAJNational Institute for Clinical Excellence and its value judgmentsBMJ2004329745922422715271836
   PubMed Web of Science ®Google Scholar
• BarhamLOrphan medicines: special treatment required?2012 Available from: http://www.2020health.org/2020health/Publications/publications-2012/Orphan-Drugs.htmlAccessed December 15, 2016
   Google Scholar
• NICENICE highly specialised technologies guidance | NICE guidance2016 Available from: https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-highly-specialised-technologies-guidanceAccessed December 15, 2016
   Google Scholar
• GarridoMVKristensenFBNielsenCPBusseRHealth technology policy-making in Europe current status, challenges and potentialWHO2008 Available from: http://www.euro.who.int/__data/assets/pdf_file/0003/90426/E91922.pdfAccessed December 10, 2016
   Google Scholar
• KaplanWWirtzVJMantel-TeeuwisseAStolkPDutheyBLaingRPriority medicines for Europe and the World 2013 Update. Available from: http://www.who.int/medicines/areas/priority_medicines/Master-DocJune28_FINAL_Web.pdfAccessed December 10, 2016
   Google Scholar
• SongPGaoJInagakiYKokudoNTangWRare diseases, orphan drugs, and their regulation in Asia: current status and future perspectivesIntractable rare Dis Res2012113925343064
   PubMedGoogle Scholar
• EURODISAbout rare diseases Available from: http://www.eurordis.org/Accessed January 11, 2017
   Google Scholar
• EURODISRare diseases: understanding this public health priority2005 Available from: http://www.eurordis.org/IMG/pdf/princeps_document-EN.pdfAccessed January 11, 2017
   Google Scholar
• EURODISMapping out the similarities and differences between rare cancers and rare diseases2015 Available from: http://www.eurordis.org/sites/default/files/rare-cancers-2015-2016.pdfAccessed January 11, 2017
   Google Scholar
• CohenJPFelixAAre payers treating orphan drugs differently?J Mark Access Heal Policy20142
   Google Scholar
• CheemaPKGavuraSMigusMGodmanBYeungLTrudeauMEInternational variability in the reimbursement of cancer drugs by publically funded drug programsCurr Oncol2012193e165e17622670106
   PubMed Web of Science ®Google Scholar
• PauwelsKHuysICasteelsMAre products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002–2012Orphanet J Rare Dis20171213628209180
   PubMed Web of Science ®Google Scholar
• MorganSGMcMahonMMittonCCentralized drug review processes in Australia, Canada, New Zealand, and the United kingdomHealth Aff (Millwood)200625233734716522575
   PubMed Web of Science ®Google Scholar
• Australian Government Department of HealthLife Saving Drugs Program (LSDP) Available from: http://www.health.gov.au/lsdpAccessed January 24, 2017
   Google Scholar
• ParisVBelloniAValue in pharmaceutical pricing country profile: Australia2014 Available from: https://www.oecd.org/health/Value-in-Pharmaceutical-Pricing-Australia.pdfAccessed January 24, 2017
   Google Scholar
• PBACGuidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.5)2015 Available from: https://pbac.pbs.gov.au/content/information/printable-files/pbacg-book.pdfAccessed December 18, 2016
   Google Scholar
• DranitsarisGPapadopoulosGHealth technology assessment of cancer drugs in Canada, the United Kingdom and Australia: should the United States take notice?Appl Health Econ Health Policy201513329130225274258
   PubMed Web of Science ®Google Scholar
• PBACPharmaceutical Benefits Scheme (PBS) | Obinutuzumab, solution for IV infusion, 1000 mg/40 mL, Gazyva®Roche Products Pty Ltd2014 Available from: http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2014-07/obinutuzumab-psd-07-2014Accessed February 9, 2017
   Google Scholar
• PBACPharmaceutical Benefits Scheme (PBS) | Obinutuzumab; 1 g/40 mL injection, 40 mL vial; Gazyva®2015 Available from: https://www.pbs.gov.au/pbs/industry/listing/elements/pbac-meetings/psd/2015-03/obinutuzumab-gazyva-psd-03-2015Accessed December 21, 2016
   Google Scholar
• PBACPharmaceutical Benefits Scheme (PBS) | Olaparib: 50 mg capsule, 4 x 112 capsules, Lynparza™2016 Available fom: http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2016-07/olaparib-psd-july-2016Accessed January 24, 2017
   Google Scholar
• PBACPharmaceutical Benefits Scheme (PBS) | Ibrutinib: 140 mg capsules, 90, Imbruvica^®2016 Available from: https://www.pbs.gov.au/pbs/industry/listing/elements/pbac-meetings/psd/2016-03/ibrutinib-imbruvica-psd-03-2016Accessed December 21, 2016
   Google Scholar
• Pharmaceutical Benefits Scheme (PBS) | Nivolumab: 40mg in 4ml (10mg/mL concentrate for IV infusion) 100mg in 10mL (10mg/mL concentrate for IV infusion), Opdivo®2016 Available from: http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2016-03/nivolumab-opdivo-non-sq-psd-03-2016Accessed January 31, 2017
   Google Scholar
• PBACPharmaceutical Benefits Scheme (PBS) | Ipilimumab: 50 mg/10 mL injection, 10 mL, 200 mg/40 mL injection, 40 mL, Yervoy®2016 Available from: https://www.pbs.gov.au/pbs/industry/listing/elements/pbac-meetings/psd/2016-07/ipilimumab-psd-july-2016Accessed December 21, 2016
   Google Scholar
• PBACPharmaceutical Benefits Scheme (PBS) | Abiraterone, tablet, 250 mg (as acetate), Zytiga® – November 20122012 Available from: https://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2012-11/abirateroneAccessed December 21, 2016
   Google Scholar
• PBACPharmaceutical Benefits Scheme (PBS) | PERTUZUMAB, 420 mg/14 mL injection, 1 x 14 mL vial Perjeta®Roche Products Pty Ltd2014 Available from: https://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2014-03/pertuzumabAccessed December 21, 2016
   Google Scholar
• ISPORPharmaceutical HTA and reimbursement processes – Canada2011 Available from: https://www.ispor.org/HTARoadMaps/CanadaPharm.aspAccessed December 15, 2016
   Google Scholar
• McKesson Canada white paperTowards a new way of evaluating orphan drugs at CADTH2016 Available from: https://www.canadianinstitute.com/wp-content/uploads/2016/07/Orphan-Drugs-at-CADTH_McKes-son.pdfAccessed December 19, 2016
   Google Scholar
• CADTHDrugs for rare diseases: evolving trends in regulatory and health technology assessment perspectives (CADTH Environmental scan)2016 Available from: https://www.canadianinstitute.com/wp-content/uploads/2016/07/Orphan-Drugs-at-CADTH_McKesson.pdfAccessed December 18, 2016
   Google Scholar
• O’SullivanAShould orphan drugs be subjected to value-based assessments?2012 Available from: https://www.ispor.org/meetings/WashingtonDC0512/releasedpresentations/IP5-Sullivan.pdfAccessed December 18, 2016
   Google Scholar
• MenonDClarkDStafinskiTReimbursement of drugs for rare diseases through the public healthcare system in Canada: where are we now?Healthc Policy2015111153226571466
   PubMedGoogle Scholar
• Health CanadaSpecial Access to drugs and health products2013 Available from: http://www.hc-sc.gc.ca/dhp-mps/acces/drugs-drogues/index-eng.phpAccessed February 9, 2017
   Google Scholar
• Health CanadaRegulatory initiative: regulations amending the food and drug regulations – orphan drugs – Forward Regulatory Plan 2016–2018 – Health Canada2016 Available from: http://www.hc-sc.gc.ca/ahc-asc/legislation/acts-reg-lois/frp-ppr/2016-2018/odrd-momr-eng.phpAccessed February 9, 2017
   Google Scholar
• CADTH pCODRGazyva for chronic lymphocytic leukemia – Details | CADTH.ca2015 Available from: https://www.cadth.ca/gazyva-chronic-lymphocytic-leukemia-detailsAccessed December 21, 2016
   Google Scholar
• CADTH pCODRImbruvica for chronic lymphocytic leukemia/small lymphocytic lymphoma (previously treated) – details | CADTH.ca2015 Available from: https://www.cadth.ca/imbruvica-chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma-previously-treated-detailsAccessed December 21, 2016
   Google Scholar
• CADTH pCODRLynparza for ovarian cancer (2nd line) – details | CADTH.ca2015 Available from: https://www.cadth.ca/lynparza-ovarian-cancer-2nd-line-detailsAccessed January 24, 2017
   Google Scholar
• CADTH pCODRCyramza for advanced GC or GEJ adenocarcinoma – details | CADTH.ca2015 Available from: https://www.cadth.ca/cyramza-advanced-gc-or-gej-adenocarcinoma-detailsAccessed January 24, 2017
   Google Scholar
• CADTH pCODRpCODR expert review committee final recommendation: nivolumab and NSCLC2016 Available from: https://www.cadth.ca/sites/default/files/pcodr/nivolumab_opdivo_nsclc_fn_rec.pdfAccessed December 21, 2016
   Google Scholar
• CADTH pCODRYervoy for advanced melanoma – details | CADTH.ca2012 Available from: https://www.cadth.ca/yervoy-advanced-melanoma-detailsAccessed December 21, 2016
   Google Scholar
• CADTH pCODRZytiga for metastatic castration resistant prostate cancer – details | CADTH.ca2013 Available from: https://www.cadth.ca/zytiga-metastatic-castration-resistant-prostate-cancer-detailsAccessed January 24, 2017
   Google Scholar
• CADTH pCODRPerjeta or perjeta-herceptin combo pack for neoadjuvant breast cancer – details | CADTH.ca2015 Available from: https://www.cadth.ca/perjeta-or-perjeta-herceptin-combo-pack-neoadjuvant-breast-cancer-detailsAccessed January 24, 2017
   Google Scholar
• KawalecPSaganAPilcAThe correlation between HTA recommendations and reimbursement status of orphan drugs in EuropeOrphanet J Rare Dis201611112227600717
   PubMed Web of Science ®Google Scholar
• NICEGuide to the methods of technology process2013 Available from: https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781Accessed December 20, 2016
   Google Scholar
• NICENational Institute for Care and Excellence interim process and methods of the highly specialised technologies programme principles2013 Available from: https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-highly-specialised-technologies-guidance/Highly-Specialised-Technologies-Interim-methods-and-process-statements.pdfAccessed December 20, 2016
   Google Scholar
• TordrupDTzoumaVKanavosPOrphan drug considerations in Health Technology Assessment in eight European countriesRare Dis Orphan Drugs2014138397
   Google Scholar
• NICETechnology appraisal processes – cancer drugs fund2016 Available from: https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisals/process-and-methods-guide-addendum.pdfAccessed December 21, 2016
   Google Scholar
• NICERapid re-consideration of drugs currently funded through the cancer drugs fund2016 Available from: https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisals/TA-CDF-reconsideration-process-March-2016-FINAL.pdfAccessed January 30, 2017
   Google Scholar
• NICEObinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia | guidance and guidelines | NICE2015 Available from: https://www.nice.org.uk/guidance/ta343Accessed December 21, 2016
   Google Scholar
• NICEIbrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation | guidance and guidelines | NICE2017 Available from: https://www.nice.org.uk/guidance/ta429Accessed January 25, 2017
   Google Scholar
• NICEOlaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy | guidance and guidelines | NICE2016 Available from: https://www.nice.org.uk/guidance/ta381Accessed December 21, 2016
   Google Scholar
• NICERamucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy2016 Available from: https://www.nice.org.uk/guidance/ta378/resources/ramucirumab-for-treating-advanced-gastric-cancer-or-gastrooesophageal-junction-adenocarcinoma-previously-treated-with-chemotherapy-82602795958981Accessed December 21, 2016
   Google Scholar
• NICEIpilimumab for previously untreated advanced (unresectable or metastatic) melanoma | guidance and guidelines | NICE2014 Available from: https://www.nice.org.uk/guidance/ta319Accessed December 21, 2016
   Google Scholar
• NICEPertuzumab for the neoadjuvant treatment of HER2-positive breast cancer | guidance and guidelines | NICE2016 Available from: https://www.nice.org.uk/guidance/ta424Accessed December 21, 2016
   Google Scholar
• NICEAbiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated2016 Available from: https://www.nice.org.uk/guidance/ta387/resources/abiraterone-for-treating-metastatic-hormonerelapsed-prostate-cancer-before-chemotherapy-is-indicated-82602854745541Accessed December 21, 2016
   Google Scholar
• RemuzatCMondherTFalissardBNew drug regulations in France: what are the impacts on market access? Part 1 Overview of new drug regulations in FranceJ Mark Access Heal Policy2013120891
   PubMedGoogle Scholar
• SorensenCDrummondMKanavosPEnsuring Value for Money in Health Care The Role of Health Technology Assessment in the European UnionWHO Regional Office for Europe: World Health Organization2008
   Google Scholar
• Douste-BlazyPMonchampM-AD’AubertFFrench National Plan for Rare Diseases 2005–20082005112004136
   Google Scholar
• HosseinZGerardATrends in cost sharing among selected high income countries – 2000–2010Health Policy20131121–2354423809913
   PubMed Web of Science ®Google Scholar
• HASCréation d ’une ALD spécifique maladies rares2005 Available from: http://www.has-sante.fr/portail/upload/docs/application/pdf/avis_ald_rapport.pdfAccessed December 18, 2016
   Google Scholar
• AggarwalAGinsburgOFojoTCancer economics, policy and politics: what informs the debate? Perspectives from the EU, Canada and USJ Cancer Policy201421111
   Google Scholar
• RémuzatCToumiMFalissardBNew drug regulations in France: what are the impacts on market access? Part 2 – impacts on market access and impacts for the pharmaceutical industryJ Mark Access Heal Policy20131
   Google Scholar
• ToumiMRémuzatCEl HammiECurrent process and future path for health economic assessment of pharmaceuticals in FranceJ Mark Access Heal Policy20153
   Google Scholar
• Haute Autorité de Santé TCHaute Autorité de Santé – IMBRUVICA (ibrutinib), Bruton’s tyrosine kinase (BTK) inhibitor2015 Available from: http://www.has-sante.fr/portail/jcms/c_2049868/en/imbruvica-ibrutinib-bruton-s-tyrosine-kinase-btk-inhibitorAccessed January 25, 2017
   Google Scholar
• Haute Autorité de Santé TCHaute Autorité de Santé – GAZYVARO (obinutuzumab) type II humanised anti-CD20 recombinant monoclonal antibody2015 Available from: http://www.has-sante.fr/portail/jcms/c_2019122/en/gazyvaro-obinutuzumab-type-ii-humanised-anti-cd20-recombinant-monoclonal-antibodyAccessed January 25, 2017
   Google Scholar
• Haute Autorité de Santé TCHaute Autorité de Santé – LYNPARZA (olaparib), PARP inhibitor2015 Available from: http://www.has-sante.fr/portail/jcms/c_2038097/en/lynparza-olaparib-parp-inhibitorAccessed January 25, 2017
   Google Scholar
• Haute Autorité de Santé TCHaute Autorité de Santé – CYRAMZA (ramucirumab), monoclonal antibody2015 Available from: http://www.has-sante.fr/portail/jcms/c_2048967/en/cyramza-ramucirumab-monoclonal-antibodyAccessed January 25, 2017
   Google Scholar
• Haute Autorité de Santé TCHaute Autorité de Santé – OPDIVO (nivolumab) anti-PD-1 antibody2016 Available from: http://www.has-sante.fr/portail/jcms/c_2639665/en/opdivo-nivolumab-anti-pd-1-antibodyAccessed January 25, 2017
   Google Scholar
• Haute Autorité de Santé TCHaute Autorité de Santé – YERVOY (ipilimumab), monoclonal antibody2014 Available from: http://www.has-sante.fr/portail/jcms/c_1779495/en/yervoy-ipilimumab-monoclonal-antibodyAccessed January 25, 2017
   Google Scholar
• HASHAS – Direction de l’Evaluation Médicale, Economique et de Santé Publique Commission: Pertuzumab2013 Available from: http://www.has-sante.fr/portail/upload/docs/evamed/CT-12851_PERJETAINS_Avis2_CT12851.pdfAccessed December 21, 2016
   Google Scholar
• HASCommission de la Transparence: zytiga2012 Available from: http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-04/zytiga_29022012_ct11654.pdfAccessed December 21, 2016
   Google Scholar
• WilkensJThulesiusHSchmidtICarlssonCThe 2015 National Cancer Program in Sweden: introducing standardized care pathways in a decentralized systemHealth Policy (New York)20161201213781382
   PubMed Web of Science ®Google Scholar
• TLVTLV: gazyvaro2014 Available from: http://www.tlv.se/lakemedel/Kliniklakemedelsuppdraget/avslutade-halsoekonomiska-bedomningar/Halsoekonomisk-bedomning-av-Gazyvaro/Accessed January 25, 2017
   Google Scholar
• TLVTLV: imbruvica2015 Available from: http://www.tlv.se/beslut/beslut-lakemedel/begransad-subvention/Imbruvica-ingar-i-hogkost-nadsskyddet-med-begransning/Accessed January 25, 2017
   Google Scholar
• TLVTLV: lynparza2015 http://www.tlv.se/beslut/beslut-lakemedel/generell-subvention/Lynparza-ingar-i-hogkostnadsskyddet/Accessed January 31, 2017
   Google Scholar
• NT CouncilNT-rådets yttrande till landstingen gällande Cyramza (ramucirumab) vid behandling av avancerad magsäckscancer eller adenokarcinom i gastroesofageala övergången2015 Available from: http://www.janusinfo.se/Documents/Nationellt_inforande_av_nya_lakemedel/Ramucirumab-(Cyramza)-151027.pdfAccessed December 21, 2016
   Google Scholar
• TLVTLV: opdivo2015 Available from: http://www.tlv.se/lakemedel/Kliniklakemedelsuppdraget/avslutade-halsoekonomiska-bedomningar/Halsoekonomisk-bedomning-av-Opdivo-vid-lungcancer/Accessed January 25, 2017
   Google Scholar
• TLVTLV: yervoy2015 Available from: http://www.tlv.se/lakemedel/Kliniklakemedelsuppdraget/avslutade-halsoekonomiska-bedomningar/Halsoekonomisk-bedomning-av-Yervoy1/Accessed January 25, 2017
   Google Scholar
• TLVTLV: perjeta2013 Available from: http://www.tlv.se/lakemedel/Kliniklakemedelsuppdraget/avslutade-halsoekonomiska-bedomningar/halsoekonomisk-bedomning-av-perjeta/Accessed January 25, 2017
   Google Scholar
• TLVTLV: Underlag för beslut om subvention -Nyansökan Zytiga (abirateron)2014 Available from: http://www.tlv.se/Upload/Beslut_2015/Underlag_beslut_zytiga.pdfAccessed December 21, 2016
   Google Scholar
• HaglundMMillerEPricing and reimbursement of novel oncology drugs in SwedenJ Mark Access Heal Policy201420
   Google Scholar
• ChafeRCulyerADobrowMAccess to cancer drugs in Canada: looking beyond coverage decisionsHealthc Policy2011632736
   PubMedGoogle Scholar
• HablCBachner ViennaFEMINET initial investigation to assess the feasibility of a coordinated system to access orphan medicines2011 Available from: http://whocc.goeg.at/Literaturliste/Dokumente/BooksReports/EMINet_InitialinvestigationOMP_updated2011.pdfAccessed February 9, 2017
   Google Scholar
• www.ema.europa.eu [homepage on the internet] Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002799/human_med_001780.jsp&mid=WC0b01ac058001d124Accessed December 15, 2016
   Google Scholar
• http://www.ema.europa.eu [homepage on the internet] Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003791/human_med_001801.jsp&mid=WC0b01ac058001d124Accessed December 15, 2016
   Google Scholar
• http://www.ema.europa.eu [homepage on the internet] Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003726/human_med_001831.jsp&mid=WC0b01ac058001d124Accessed December 15, 2016
   Google Scholar
• http://www.ema.europa.eu [homepage on the internet] Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002829/human_med_001825.jsp&mid=WC0b01ac058001d124Accessed December 15, 2016
   Google Scholar
• http://www.ema.europa.eu [homepage on the internet] Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003985/smops/Positive/human_smop_001119.jsp&mid=WC0b01ac058001d127Accessed December 15, 2016
   Google Scholar
• http://www.ema.europa.eu [homepage on the internet] Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002213/human_med_001465.jsp&mid=WC0b01ac058001d124Accessed December 15, 2016
   Google Scholar
• www.ema.europa.eu [homepage on the internet] Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002547/human_med_001628.jsp&mid=WC0b01ac058001d124Accessed December 15, 2016
   Google Scholar
• www.ema.europa.eu [homepage on the internet] Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002321/human_med_001499.jsp&mid=WC0b01ac058001d124Accessed December 15, 2016
   Google Scholar
• NHS EnglandUK Strategy for Rare Diseases NHS England Statement of Intent https://www.england.nhs.uk/wp-content/uploads/2014/02/rare-dis-stat-intent.pdf. Published 2014Accessed December 20, 2016
   Google Scholar